Funding Correction Clarifies Support for Rat Model Allergic Rhinitis Study
An erratum in International Archives of Allergy and Immunology corrected the funding statement attached to a rat-model study examining how adipose tissue-derived mesenchymal stem cells regulate Th17/Treg balance in allergic rhinitis through the IL-2/JAK-3/STAT-5 signaling pathway. The correction does not change the biological premise of the original paper or its title-level scientific claim; it repairs the administrative record so the paper carries the proper financial disclosures.
Funding accuracy is not a cosmetic detail in translational immunology. Studies involving cellular therapy, immune signaling, and animal models depend on clear disclosure because readers need to know which institutions supported the work and whether multiple public grants contributed to the project. In this case, the corrected statement lists a broad set of Chinese funding bodies and training programs, replacing the incomplete information that appeared in the published article.
The corrected funding sources include the Scientific Research and Innovation Fund Project of Gansu University of Chinese Medicine (2020KCZD-7), the Lanzhou Talent Innovation and Entrepreneurship Project (2021-RC-129), the Gansu Province Health Industry Outstanding Young Talent Project (GSWSQN2021-002), the National Natural Science Foundation of China (82260475), and the Key Project of the National Research Project Cultivation Plan of Gansu Provincial People’s Hospital (19SYPYA-13). Additional support came from the Hospital Fund of The First Hospital of Lanzhou University (ldyyyn2021-70), the Natural Science Foundation of Gansu Province (24JRRA1081), the Natural Science Foundation of Gansu Province (21JR1RA153), the Natural Science Foundation of Gansu Province (21JR7RA363), the Natural Science Foundation of Gansu Province (23JRRA1634), and the Cuiying Scientific Training Program for Undergraduates of The Second Hospital Clinical Medical School, Lanzhou University (20210050006).
One sentence captures the practical consequence of the erratum: the study’s funding trail is now complete.
Why the Correction Matters in Translational Allergy Research
The underlying study sits in a biologically plausible area of airway immunology. Allergic rhinitis is driven by dysregulated immune responses in which helper T-cell subsets and regulatory T cells can fall out of balance, allowing inflammatory signaling to persist in the nasal mucosa. The title of the original article places Th17/Treg regulation at the center of that process and ties the effect to IL-2/JAK-3/STAT-5 signaling, a pathway closely linked to immune-cell proliferation, differentiation, and regulatory control.
In that context, mesenchymal stem cells from adipose tissue are being explored not as a decorative laboratory finding but as a mechanistic intervention. Cellular therapies are often studied because they may recalibrate inflammatory networks rather than simply suppress a single mediator. When investigators test such a pathway in a rat model, transparency around funding becomes part of the scientific chain of custody: it tells readers how the work was supported, where the resources came from, and which institutions invested in the project from conception through publication.
The corrected disclosure also matters for institutional accountability. Multiple grants from university, hospital, provincial, and national programs often reflect collaborative infrastructure rather than a single sponsor. In an area as technically specific as immune-cell signaling, that kind of support can shape access to laboratory platforms, animal facilities, molecular assays, and training pipelines for junior investigators. Readers assessing the paper’s credibility should be able to see that support clearly and accurately.
What the Erratum Adds to the Published Record
Errata are often short, but their function is serious. They preserve the reliability of the literature by fixing details that can affect indexing, compliance, and disclosure review. Here, the correction is confined to funding information, and the record now identifies the full set of sponsors attached to the 2025 article by Hou and colleagues.
Because the erratum does not revise the experimental design, endpoints, animal findings, or mechanistic conclusions, it leaves the scientific claims untouched. The focus remains on the same immunologic question: whether adipose-derived mesenchymal stem cells can shift the Th17/Treg axis and influence IL-2/JAK-3/STAT-5 signaling in a rat model of allergic rhinitis. The correction simply ensures that the administrative metadata matches the actual support behind that work.
In publication ethics, that separation matters. Experimental interpretation can be debated on its own merits, while funding information must be exact. A corrected grant list may seem mundane beside a cellular therapy paper, but it is part of the evidentiary frame surrounding the research. Without it, readers lose a piece of context that belongs in every transparent biomedical report.
The Scientific Question Remains the Same
The original title points to a focused mechanistic hypothesis: adipose tissue-derived mesenchymal stem cells may influence immune balance by activating IL-2/JAK-3/STAT-5 signaling and thereby regulate Th17/Treg cells. In allergic rhinitis, that kind of pathway-level approach is attractive because it targets immune imbalance rather than symptoms alone. If validated beyond an animal model, it could inform how researchers think about immune recalibration in airway allergy.
For now, the erratum stays within its lane. It does not claim efficacy, it does not add new data, and it does not modify the original article’s biology. It does, however, complete the public record for a study that sits at the intersection of allergy immunology, stem cell biology, and signaling-pathway research. In a field where methods, grants, and reproducibility are tightly linked, that correction is part of the science, not an afterthought.
The article’s experimental conclusions will continue to stand or fall on the strength of the original data. The funding statement now stands on firmer ground as well.